LRAD +18% . PGEM +16% . WHX +16% . MELI +15% . SHOR +14% . Top 10 Losers: MBII -43% . IRG -32% . HGR -28% . VOLC -26% . RBCN -24% . POST -18% . ALXA -18% . EAC -18% . SEM -18% . RATE -17% . Post your comment!
Alexza Pharmaceuticals ( ALXA -21.8% ) Q2 results : Revenues: $1.5M (-96.6%); Operating Expenses: $12.8M (+2.1%); Operating Loss
The following audio is from a conference call that will begin on August 07, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Alexza Pharma (NASDAQ: ALXA ): Q2 EPS of -$0.34 beats by $0.33 . Revenue of $1.48M (-96.6% Y/Y) misses by $0.76M . Shares -2% . Press Release Post your comment!
(Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.
Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain
We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third
Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing
We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development